VERIFIED · FEDERALREGISTER.GOV

FDA Determines ANSAID (Flurbiprofen) Tablets Were Not Withdrawn for Safety or Effectiveness

NoticeHealth and Human Services DepartmentAugust 17, 2026

By Christopher Smoot, Founder & Editor · Last verified against source: August 17, 2026

Plain-English Summary

The FDA announced that ANSAID (flurbiprofen) tablets, both 50 mg and 100 mg strengths, have not been removed from the market due to safety or efficacy concerns. This finding is documented in a formal notice dated August 14, 2026. The determination clears the way for the agency to approve abbreviated new drug applications for these products, provided all other regulatory requirements are satisfied. No other actions or changes to the product’s status are indicated in the notice.

Current Status

This is a final notice from the Health and Human Services Department, not a proposed rule or open comment period.

What This Means

By stating that the tablets were not withdrawn for safety or effectiveness, the FDA removes a regulatory barrier that could have prevented generic manufacturers from filing ANDAs. The language “will allow FDA to approve abbreviated new drug applications…if all other legal and regulatory requirements are met” signals that the agency is now prepared to evaluate generic submissions for flurbiprofen tablets. Existing branded products can continue to be sold without interruption. Manufacturers seeking to market generic versions must still satisfy labeling, manufacturing, and bioequivalence standards. The notice does not alter the product’s approved labeling or marketing status beyond the ANDA pathway.

Who Is Affected

Brand‑name manufacturers of ANSAID tablets must now consider potential competition from generic entrants. Generic drug companies can submit ANDAs for 50 mg and 100 mg flurbiprofen tablets, expanding their product pipelines. The FDA’s Office of Generic Drugs will handle the review of these applications. Patients and prescribers may eventually benefit from lower‑cost generic options, though the notice itself does not change current pricing or availability.

Background

The notice responds to a procedural requirement that the FDA confirm whether a drug has been withdrawn for safety or effectiveness before allowing ANDA approvals. Prior to this determination, the withdrawal status of ANSAID tablets was unclear, potentially delaying generic competition. The agency’s clarification aligns with the Food, Drug, and Cosmetic Act, which mandates such determinations as a precondition for generic approval. The timing coincides with the agency’s broader effort to reduce drug costs by facilitating generic market entry.

Arguments For

Ensuring that the tablets were not withdrawn removes an unnecessary obstacle to generic competition, which can lower drug prices and increase patient access. The determination is based on a factual safety and efficacy assessment, supporting the statutory goal of promoting affordable medicines while maintaining safety standards.

Arguments Against

The abstract provides no indication of controversy or opposition; therefore, there are no identified substantive concerns from stakeholders within the notice itself.

Economic Considerations

If generic manufacturers file ANDAs and receive approval, competition could drive down the price of flurbiprofen tablets, potentially generating savings for insurers and patients. The extent of price reductions will depend on market uptake and the number of generic entrants. Existing branded manufacturers may experience reduced market share, which could affect revenue but also encourage efficiency. Because the notice does not include a formal economic analysis, these effects remain speculative.

Sections beyond the plain-English summary are AI-synthesized analysis based on the sourced Federal Register filing, read, edited where needed, and approved by a human editor before publication. Full methodology: Editorial & Methodology.

← All Records